Press Releases

• Preparation displays good tolerability and safety
• Study goals attained with fewer patients than planned
• Follow-up studies in planning

The biotechnology company MOLOGEN AG has expanded its scientific advisory board. With Stefan M. Manth, MD, PhD, MBA, the advisory committee has been joined by a top manager from the pharmaceutical industry with extensive experience in the strategic...

•  Economic development running according to plan

• Compound shows very good tolerability and safety
• Efficacy data much better than expected

• Phase II/III of colorectal cancer study with MGN1703 have also begun in Russia
• Clinical study II/III for the treatment of lung cancer under preparation

• Application for pivotal phase II/III clinical trial in preparation
• Expansion of the product pipeline with further blockbuster candidate
• Lung cancer is one of the most prevalent forms of cancer worldwide

• Revenues of 10 million euro from capital increase
• European patent for renal cancer medicine MGN1601
• Further clinical trial being planned with MGN1703 in new cancer indication